The intraventricular injection of an antisense oligonucleotide to knock down NEAT1 significantly reduced brain damage by reducing activated microglia and proinflammatory cytokines in a mouse model of ischemic stroke, supporting NEAT1 as a potential therapeutic target for ischemic stroke treatment [115,116]. Here, NEAT1 is linked to ischemic stroke.